Distinctive clinical and histologic features in cutaneous melanoma with copy number gains in 8q24

American Journal of Surgical Pathology

Volumn 36, Issue 2, 2012, Pages 253-264

  Pouryazdanparast, Pedram ^a   Cowen, D Patrick ^a   Beilfuss, Beth Ann ^a   Haghighat, Zahra ^a   Guitart, Joan ^a   Rademaker, Alfred ^a   Gerami, Pedram ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

BRAF; Fluorescence in situ hybridization; Melanoma; Mutation; MYC; NRAS

Indexed keywords

MYC PROTEIN; MYC PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; MALE; MELANOMA; MIDDLE AGED; MUTATION; PATHOLOGY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-MYC; SKIN NEOPLASMS;

EID: 84857743726     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31823425cc     Document Type: Article

References (23)

1. Bauer J, Buttner P, Murali R, et al, BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011;24:345-351.
2. Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 2008;21:27-38. (Pubitemid 351421467)
3. Gammon B, Beilfuss B, Guitart J, et al. Enhanced detection of spitzoid melanomas using fluorescence in situ hybridization. Am J Surg Pathol. 2011 (In Press).
4. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol. 2009;33:1146-1156.
5. Gerami P, Jewell SS, Pouryazdanparast P, et al, Copy number gains in 11q13 and 8q34 are highly linked to prognosis in cutaneous malignant melanoma. J Mol Diagn. 2011;13:352-358.
6. Gorden A, Osman I, Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 2003;63: 3955-3957. (Pubitemid 36917911)
7. Halaban R. Pigmentation in melanomas: changes manifesting underlying oncogenic and metabolic activities. Oncol Res. 2002;13:3-8. (Pubitemid 38166399)
8. Kim A, Yang Y, Lee MS, et al. NDRG2 gene expression in B16F10 melanoma cells restrains melanogenesis via inhibition of Mitf expression. Pigment Cell Melanoma Res. 2008;21:653-664.
9. Lee JH, Choi JW, Kim YS, Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta-analysis. Br J Dermatol. 2011;164: 776-784.
10. Singer G, Oldt R, 3rd Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484-486. (Pubitemid 36432423)
11. Vachtenheim J, Borovansky J, "Transcription physiology"; of pigment formation in melanocytes: central role of MITF. Exp Dermatol. 2010;19:617-627.
12. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008;5:e120.
13. Weinberg RA. The Biology of Cancer. New York: Garland Science; 2007.
14. Zhuang Z, Bertheau P, Emmert-Buck MR, et al. A microdissection technique for archival DNA analysis of specific cell populations in lesions <1mm in size Am J Pathol 1995 146 620-625
15. Busam KJ, Kucukgol D, Sato E, et al. Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers. Am J Surg Pathol. 2005;29: 400-406. (Pubitemid 40321977)
16. Cohen-Knafo E, Al-Saati T, Aziza J, et al. Production and characterization of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections. J Clin Pathol. 1995;48:826-831.
17. Kaufmann O, Koch S, Burghardt J, et al. Tyrosinase, Melan-A, and KBA 62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11:740-746. (Pubitemid 28381608)
18. Horn LC, Einenkel J. Uterine perivascular epitheloid cell tumor (PEComa) with CD117 and PNL2 positivity and entrapped endometriotic glands, mimicking sex-cordlike differentiation. Ann Diagn Pathol. 2011;15:216-8.
19. Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 2001;25:205-211. (Pubitemid 32167502)
20. Morris LG, Wen YH, Nonaka D, et al. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck. Head Neck. 2008;30:771-775. (Pubitemid 351913854)
21. Nonaka D, Laser J, Tucker R, et al. Immunohistochemical evaluation of necrotic malignant melanomas. Am J Clin Pathol. 2007; 127:787-791.
22. Pages C, Pochaic P, al Saati T, et al. KBA.62: A useful marker for primary and metastatic melanomas. Hum Pathol. 2008;39:1136-1142.
23. Rochaix P, Lacroix-Triki M, Lamant L, et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Mod Pathol. 2003;16:481-490. (Pubitemid 36618469)